Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05474729
PHASE1/PHASE2

Minocycline for Chronic Autoimmune Uveitis

Sponsor: Sun Yat-sen University

View on ClinicalTrials.gov

Summary

Autoimmune uveitis is one kind of non-infectious, sight-threatening, relapsing and severe ocular disease. Approximately 20%-25% autoimmune uveitis patients suffer from the dilemma of blindness for the chronic and persistent inflammatory state in the eyes, which results in continuous destroy in the structure of the eyes and gradually leads to irreversible damage on visual function. However, it shows limiting efficacy of current treatment including glucocorticoids, immunosuppressant and biologics for chronic autoimmune uveitis. Minocycline has been regarded to have anti-apoptosis and immunemodulatory function for decades and it has been illustrated to be beneficial in several neuro-degenerative and neuro-inflammatory diseases. This trial aims to investigate the efficacy and safety of minocycline for chronic autoimmune uveitis with retinal degenerative changes.

Official title: The Efficacy and Safety of Minocycline for Chronic Autoimmune Uveitis

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

10

Start Date

2021-12-01

Completion Date

2026-12-31

Last Updated

2023-04-18

Healthy Volunteers

No

Interventions

DRUG

minocycline

minocycline capsule 100mg per day orally

Locations (1)

Zhongshan Ophthalmic Center

Guangzhou, Guangdong, China